Supernus to Participate in Two Upcoming Investor Conferences

Company Overview - Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3][4] - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] Upcoming Events - Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the Barclays Global Healthcare Conference on March 11, 2025, with a fireside chat scheduled for 12:30 p.m. ET [1] - The company will also be present at the Jefferies Biotech on the Beach Summit on March 12, 2025 [1] Investor Relations - A live audio webcast of the fireside chat at the Barclays Global Healthcare Conference will be available on the company's website, with an archived replay accessible for 60 days post-conference [2]